Lido Advisors’s Relmada Therapeutics RLMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$52.1K Sell
13,827
-78
-0.6% -$383 ﹤0.01% 2013
2026
Q2
$96.2K Hold
13,905
– – ﹤0.01% 2042
2026
Q1
$96.8K Hold
13,905
– – ﹤0.01% 1864
2025
Q4
$27.9K Hold
13,905
– – ﹤0.01% 1908
2025
Q3
$27.9K Hold
13,905
– – ﹤0.01% 1810
2025
Q2
$8.35K Hold
13,905
– – ﹤0.01% 1648
2025
Q1
$3.75K Buy
+13,905
New +$4.61K ﹤0.01% 1505

Other funds holding RLMD

Lido Advisors's RLMD Position: Q3 2026 in Review

Lido Advisors reduced its Relmada Therapeutics (RLMD) stake by 0.56% in Q3 2026, selling an estimated $383 and leaving 13,827 shares worth $52.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2013.

Lido Advisors first reported a position in RLMD in Q1 2025 and has held it in 7 quarters since. The position peaked at $96.8K in Q1 2026. 135 funds tracked by Wall St. Rank hold RLMD as of Q3 2026.

  • Lido Advisors held 13,827 shares of Relmada Therapeutics worth $52.1K as of Q3 2026.
  • Lido Advisors sold 78 Relmada Therapeutics shares in Q3 2026, an estimated $383.
  • Relmada Therapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q3 2026, its #2013 holding.
  • Lido Advisors first reported a position in Relmada Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Lido Advisors's Relmada Therapeutics position peaked at $96.8K in Q1 2026.
  • 135 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2026.

Based on Lido Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.